SOUTH SAN FRANCISCO, CA and TOKYO, JAPAN -- (MARKET WIRE) -- 11/07/2005 -- Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma Inc. announced today that they have entered into a collaboration for the development and commercialization of Theravance’s investigational antibiotic, telavancin. Telavancin is a novel lipoglycopeptide injectable antibiotic discovered by Theravance that targets serious Gram-positive infections including drug-resistant Staphylococcus aureus strains. Previously presented data demonstrated that telavancin has a unique multifunctional mechanism of action that the companies believe results in bacterial killing and may help reduce the risk of inducing resistance. Telavancin is currently in Phase 3 studies for the treatment of complicated skin and skin structure infections (cSSSI) and Hospital-Acquired Pneumonia (HAP).
